Recent studies show microbiome modulation boosts chemotherapy accumulation, peptide-based mRNA vaccines shrink neuroblastoma tumors by 70%, and engineered LNPs enhance lymph node delivery while cutting side effects.
MSD said sacituzumab tirumotecan improved overall survival and progression-free survival in the Phase III TroFuse-005 trial in endometrial cancer. The study also met its objective response rate endpoint.
A randomized trial of 210 advanced lung cancer patients found that administering checkpoint inhibitor immunotherapy in the morning nearly doubled progression-free survival and extended overall survival by nearly a year compared to later-day dosing.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07753642 |
Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07743632 |
Neoadjuvant Angiogenesis-Targeting Bispecific Chemoimmunotherapy for TNBC |
NOT_YET_RECRUITING | PHASE2 |
| NCT07724457 |
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07719855 |
A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma |
NOT_YET_RECRUITING | PHASE3 |
| NCT07714421 |
Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients |
NOT_YET_RECRUITING | PHASE1 |
| NCT07712588 |
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07662928 |
Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study |
NOT_YET_RECRUITING | PHASE2 |
| NCT07654426 |
The CARDIOPROTECT Trial |
RECRUITING | PHASE2 |
| NCT07638787 |
Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07636564 |
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment |
NOT_YET_RECRUITING | PHASE2 |
